A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bio Atla, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,700 shares of BCAB stock, worth $4,401. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,700
Previous 20,200 86.63%
Holding current value
$4,401
Previous $69,000 95.65%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.37 - $3.92 $154,344 - $441,627
112,660 Added 155.1%
185,297 $253,000
Q1 2024

May 15, 2024

SELL
$1.88 - $3.46 $955 - $1,757
-508 Reduced 0.69%
72,637 $249,000
Q4 2023

Feb 14, 2024

SELL
$1.27 - $3.18 $52,710 - $131,982
-41,504 Reduced 36.2%
73,145 $179,000
Q3 2023

Nov 14, 2023

SELL
$1.7 - $3.07 $30,168 - $54,480
-17,746 Reduced 13.4%
114,649 $194,000
Q2 2023

Aug 14, 2023

SELL
$2.83 - $3.87 $1.08 Million - $1.47 Million
-380,239 Reduced 74.17%
132,395 $397,000
Q1 2023

May 15, 2023

BUY
$2.3 - $8.25 $1.03 Million - $3.68 Million
446,091 Added 670.38%
512,634 $1.37 Million
Q4 2022

Feb 14, 2023

SELL
$6.29 - $11.01 $87,896 - $153,853
-13,974 Reduced 17.36%
66,543 $548,000
Q3 2022

Nov 14, 2022

SELL
$2.94 - $11.87 $289,210 - $1.17 Million
-98,371 Reduced 54.99%
80,517 $620,000
Q2 2022

Aug 15, 2022

BUY
$2.13 - $5.38 $165,875 - $418,972
77,876 Added 77.1%
178,888 $510,000
Q1 2022

May 16, 2022

BUY
$4.38 - $18.78 $256,825 - $1.1 Million
58,636 Added 138.37%
101,012 $505,000
Q4 2021

Feb 14, 2022

BUY
$19.0 - $30.95 $805,144 - $1.31 Million
42,376 New
42,376 $0
Q3 2021

Nov 15, 2021

SELL
$29.44 - $43.74 $4.5 Million - $6.69 Million
-152,999 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$38.07 - $56.17 $2.63 Million - $3.88 Million
69,080 Added 82.32%
152,999 $0
Q1 2021

May 17, 2021

SELL
$32.41 - $70.91 $3.29 Million - $7.19 Million
-101,403 Reduced 54.72%
83,919 $4.27 Million
Q4 2020

Feb 16, 2021

BUY
$31.02 - $35.16 $5.75 Million - $6.52 Million
185,322 New
185,322 $6.3 Million

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $59.2M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.